Ujvira 100mg

Ujvira 100mg Injection is a brand name for Trastuzumab Emtansine, a medication used to treat certain types of breast cancer. It is an antibody-drug conjugate that targets the HER2 protein, which is overexpressed in many breast cancers.

Composition:

Each 100mg vial of Ujvira 100mg Injection contains Trastuzumab Emtansine, a combination of the monoclonal antibody trastuzumab and the microtubule inhibitor emtansine.

Mechanism of Action: Trastuzumab Emtansine works by binding to the HER2 protein on cancer cells, which then triggers the release of a toxic payload that kills the cells. The medication is designed to target and kill cancer cells while minimizing harm to healthy cells.

Indications: Ujvira 100mg Injection is used to treat:

1. HER2-positive breast cancer in patients who have received prior treatment with trastuzumab and chemotherapy.
2. Breast cancer in patients who have received prior treatment with trastuzumab and chemotherapy, and who have progressed or relapsed after treatment with trastuzumab and docetaxel.

Dosage: The recommended dosage of Ujvira 100mg Injection is:

1. Initial dose: 8 mg/kg (100 mg) administered as an intravenous infusion over 30-90 minutes.
2. Subsequent doses: 6 mg/kg (100 mg) administered as an intravenous infusion over 30-90 minutes every 3 weeks.

Side Effects: Common side effects of Ujvira 100mg Injection include:

1. Nausea
2. Fatigue
3. Hair loss
4. Diarrhea
5. Vomiting
6. Abdominal pain
7. Fever
8. Chills
9. Increased risk of serious infections, such as pneumonia and sepsis

Recommendation: Ujvira 100mg Injection should be administered under the guidance of an experienced healthcare provider, usually an oncologist or hematologist. Patients should be monitored for signs of side effects and toxicity.

Important Note:

• Ujvira 100mg Injection may cause severe allergic reactions, including anaphylaxis.
• Patients with a history of severe allergic reactions or those who are taking immunosuppressive medications should be cautious when using Ujvira 100mg Injection.
• Women of childbearing potential should avoid pregnancy during treatment with Ujvira 100mg Injection due to the risk of fetal harm.
• Patients with pre-existing kidney or liver disease should be monitored closely during treatment with Ujvira 100mg Injection due to the risk of worsening kidney or liver function.

It’s important to note that this information is intended to serve as a general overview of Ujvira 100mg Injection and its uses, and should not be considered a substitute for medical advice from a qualified healthcare provider or oncologist.